Hims & Hers Health, Inc. (NYSE:HIMS) is among the 7 Best Beauty Stocks to Buy Right Now. TheFly reported on January 8, 2026, ...

The stock boasts the one year return of 34.3%, in contrast to 16.4% for the S&P 500. This situation necessitates a ...

Hims & Hers Health (HIMS) is back in focus as investors reassess its telehealth model, weighing GLP-1 related interest and ...

Hims & Hers stock has nosedived in the past few months. It has dived by over 56% from its highest point in July last year and ...

Amazon Pharmacy's low-priced Wegovy rollout raises fresh concerns about pricing power and market share for telehealth players ...

Hims & Hers was rated Hold amid margin pressure, Amazon-driven competition, & uncertain catalysts. Learn more about HIMS ...

Hims & Hers Health, Inc. is rated a Buy with strong subscriber growth and rising revenue per subscriber. Learn more about ...

Shares of telemedicine provider Hims & Hers are under significant pressure, with investor anxiety mounting despite the company's impressive growth metrics. The catalyst for this unease is a strategic ...

Based on current trajectories, analysts project that HIMS stock could reach $52 by December 2027, representing a potential 65% return from its current price of $32. The company’s Q3 revenue of $600 ...

The core challenge for Hims & Hers stems from escalating competition. Amazon Pharmacy has disrupted the market by launching a low-cost offering for weight-loss therapies similar to Wegovy. Market ...